Association of elevated serum carbohydrate antigen 19‐9 levels with extensive interstitial lung disease in patients with systemic sclerosis: A cross‐sectional study

Abstract

AbstractAimTo assess the usefulness of carbohydrate antigen 19‐9 (CA19‐9) as a biomarker for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD), using serum samples and clinical parameters of patients with SSc.MethodsPatients with SSc admitted to Tokyo Women's Medical University Hospital between 2010 and 2021 and those who underwent chest computed tomography (CT) were included. Patients were diagnosed with ILD based on chest CT findings, and SSc‐ILD was categorized as either a limited or extensive disease based on chest CT and pulmonary function test findings. Serum CA19‐9 levels were measured in 56 patients with SSc and in 32 healthy individuals. Additionally, we evaluated the difference in serum CA19‐9 levels between the groups, the correlation with ILD area and pulmonary function, and discriminative performance to diagnose extensive ILD.ResultsOf the 56 patients with SSc, 40 (71.4%) had ILD, and 17 (30.4%) were classified as having extensive disease. Serum CA19‐9 levels were significantly elevated in patients with extensive disease compared to those with limited disease (median [interquartile range]: 25.7 U/mL [10.1–50.8] vs. 8.8 U/mL [4.5–17.6], p = .02) and correlated with ILD area (r = .30, p = .02). There was no significant correlation between serum CA19‐9 level and pulmonary function. The cutoff of CA19‐9 for the diagnosis of the extensive disease was determined to be 19.8 U/mL, with a sensitivity of 64% and specificity of 82% and an area under the curve of 0.74 (95% confidence interval 0.58–0.90).ConclusionThe serum CA19‐9 level may be a useful marker for identifying patients with SSc‐ILD with extensive disease.